Supply Chain
New research from Advisory Board, conducted in partnership with Staples Business, reveals how 102 health system supply chain and executive…
Pfizer on Wednesday filed an antitrust suit against Johnson & Johnson, claiming the drugmaker's "exclusionary contracts" with insurers and hospitals unfairly blocked competition for J&J's arthritis drug Remicade, reports The Wall Street Journal.
An Alaska union-benefits fund filed a federal lawsuit Monday against Abbott Laboratories, claiming the company' subsidiary, St. Jude Medical, failed to warn regulators and patients about defective lithium batteries in its defibrillators for years, reports StarTribune.
Amazon is reportedly communicating with pharmacy benefit managers about potential drug contracts, according to a Leerink Partners analysis cited by CNBC.
The world has a severe lack of new antibiotics being developed to combat antimicrobial resistance, according to a recent report by the World Health Organization.
The FDA approved United Kingdom-based GlaxoSmithKline's Trelegy Ellipta, a once-daily inhaler that contains three medicines for chronic obstructive pulmonary disease.
Israel-based Teva Pharmaceuticals will sell its remaining women's health assets in two deals, totaling $1.38 billion, according to the Philadelphia Business Journal.
The Food and Drug Administration on Tuesday approved Teligent's triamcinolone acetonide cream.
Symbiomix Therapeutics on Monday earned Food and Drug Administration approval for its antibiotic Solosec.
The Food and Drug Administration has approved seven biosimilars drugs since 2015, but only three are on the market, reports Bloomberg.
The National Institutes of Health allocated about $15 million in funding to 13 two-year research initiatives creating 3-D microphysiological system platforms that model human disease.